Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ONE Bio Corp. (ONBI)
Aventura, FL, US
ONE Bio Corp. functions as an agritech enterprise that, alongside its subsidiaries, employs eco-friendly manufacturing methods to develop and produce foundational chemicals, botanical extracts, health supplements, and organic goods. The company's operations are divided into two primary segments: Chemical and Herbal Extracts (CHE) and Organic Products (OP). The CHE division is dedicated to the creation, production, and market introduction of bio-ecological and non-prescription items. These products are formulated using compounds extracted from tobacco leaves and various other plant sources. Its offerings encompass chemical extracts such as Solanesol and Coenzyme Q10, in addition to herbal extracts like Resveratrol, 5-Hydroxytryptophan, and Ganoderma Tea, alongside granular and powdered fertilizers. Distribution for CHE products within China's bio-health and raw chemical intermediates sectors occurs through a network of independent third-party distributors, academic institutions, and hospital research facilities. Meanwhile, the OP unit manufactures a diverse array of health and energy beverages for both consumer and commercial use, organic food products, and fertilizers. These products, primarily bamboo-based, are marketed within the People's Republic of China. Its portfolio includes standard and vacuum-packed canned bamboo shoots, prepared mixed and seasoned vegetables, and the Japanese rice delicacy known as Kamameshi. This segment delivers its merchandise directly to supermarket chains, hotels, hospitals, and restaurants, augmented by sales through independent third-party distributors. Globally, ONE Bio Corp. exports its products to Japan, various Southeast Asian nations, European markets, and North America. Founded in 2000, the company was rebranded from ONE Holdings, Corp. to ONE Bio Corp. in November 2009 and is based in Aventura, Florida.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | 0.00% | 0.00% | 0.00% | +150.00% | 0.00% | +150.00% | -90.00% | -97.49% | -95.05% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+136.9% ★ Q3'11: +0.3% (vs Q3'10)
-
EPS growth Biotechnology: +29.7%+45.2% ★ Q3'11: -24.1% (vs Q3'10)
-
FCF margin FCF growth · Biotechnology: +16.2%+10.5% ★ Q3'11: +38.5% (vs Q3'10)
-
EBIT margin Biotechnology: +0.0%+24.8% ★ Q3'11: +21.7% (vs Q3'10)
-
ROIC Biotechnology: -16.1%+18.4% ★ Q3'11: +13.7% (vs Q3'10)
-
Share dilution Biotechnology: -3.4%+25.5% Q3'11: +24.3% (vs Q3'10)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×1.45× Q3'11: 1.94× (vs Q3'10)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jerold Siegan | General Counsel | — | male |
| Jian Ming Chan | Chairman of the Advisory Board & Chief Scientist | — | — |
| Min Zhao | Director & President of China Operations | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ONBI
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
